Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Ionis Pharmaceuticals (IONS) and Dexcom (DXCM)

Tipranks - Tipranks - Wed Apr 22, 7:22AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY), Ionis Pharmaceuticals (IONS) and Dexcom (DXCM) with bullish sentiments.

Claim 30% Off TipRanks

Eli Lilly & Co (LLY)

Bernstein analyst Courtney Breen assigned a Buy rating to Eli Lilly & Co yesterday and set a price target of $1300.00. The company’s shares closed last Monday at $919.90.

According to TipRanks.com, Breen is a 4-star analyst with an average return of 15.3% and a 81.3% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Merck & Company, and Gilead Sciences. ;'>

Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average price target of $1247.71, a 34.6% upside from current levels. In a report issued on April 5, TipRanks – xAI also upgraded the stock to Buy with a $1038.00 price target.

See today’s best-performing stocks on TipRanks >>

Ionis Pharmaceuticals (IONS)

Morgan Stanley analyst Michael Ulz reiterated a Buy rating on Ionis Pharmaceuticals today and set a price target of $130.00. The company’s shares closed last Monday at $74.87.

According to TipRanks.com, Ulz is a 3-star analyst with an average return of 2.2% and a 44.5% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Aardvark Therapeutics, Inc., Kyverna Therapeutics, Inc., and Arrowhead Pharmaceuticals. ;'>

Currently, the analyst consensus on Ionis Pharmaceuticals is a Strong Buy with an average price target of $103.67, implying a 37.3% upside from current levels. In a report issued on April 10, Raymond James also initiated coverage with a Buy rating on the stock with a $104.00 price target.

Dexcom (DXCM)

In a report released yesterday, David Roman from Goldman Sachs maintained a Buy rating on Dexcom, with a price target of $82.00. The company’s shares closed last Monday at $64.62, close to its 52-week low of $62.34.

According to TipRanks.com, Roman is a 1-star analyst with an average return of -3.2% and a 44.7% success rate. Roman covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., GE Healthcare Technologies Inc, and Bausch + Lomb Corporation. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dexcom with a $86.24 average price target, which is a 35.7% upside from current levels. In a report issued on April 6, TipRanks – xAI also upgraded the stock to Buy with a $71.00 price target.

Read More on LLY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).